Stoke Therapeutics (STOK) Stock Forecast, Price Target & Predictions
STOK Stock Forecast
Stoke Therapeutics stock forecast is as follows: an average price target of $26.50 (represents a 152.14% upside from STOK’s last price of $10.51) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
STOK Price Target
The average price target for Stoke Therapeutics (STOK) is $26.50 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $35.00 to $18.00. This represents a potential 152.14% upside from STOK's last price of $10.51.
STOK Analyst Ratings
According to 6 Wall Street analysts, Stoke Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for STOK stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Stoke Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 11, 2024 | Marc Goodman | Leerink Partners | $18.00 | $11.84 | 52.03% | 71.27% |
| Sep 11, 2024 | Debjit Chattopadhyay | H.C. Wainwright | $35.00 | $15.32 | 128.46% | 233.02% |
| May 07, 2024 | Sumant Kulkami | Canaccord Genuity | $20.00 | $11.87 | 68.49% | 90.29% |
| Mar 26, 2024 | Joseph Stringer | Needham | $22.00 | $6.50 | 238.46% | 109.32% |
| Mar 26, 2024 | Sumant Kulkami | Canaccord Genuity | $21.00 | $10.92 | 92.31% | 99.81% |
| Nov 14, 2022 | Needham | $25.00 | $9.33 | 167.95% | 137.87% | |
| Apr 26, 2021 | Judah Frommer | Credit Suisse | $58.00 | $32.50 | 78.46% | 451.86% |
The latest Stoke Therapeutics stock forecast, released on Oct 11, 2024 by Marc Goodman from Leerink Partners, set a price target of $18.00, which represents a 52.03% increase from the stock price at the time of the forecast ($11.84), and a 71.27% increase from STOK last price ($10.51).
Stoke Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 5 |
| Avg Price Target | - | - | $23.20 |
| Last Closing Price | $10.51 | $10.51 | $10.51 |
| Upside/Downside | -100.00% | -100.00% | 120.74% |
In the current month, the average price target of Stoke Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Stoke Therapeutics's last price of $10.51. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 11, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 11, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 28, 2024 | Needham | Buy | Buy | Hold |
| Jun 28, 2024 | Canaccord Genuity | Underperform | Underperform | Hold |
| May 07, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| May 06, 2024 | Wedbush | Buy | Buy | Hold |
| May 06, 2024 | Needham | Underperform | Underperform | Hold |
| Apr 04, 2024 | Needham | Underperform | Underperform | Hold |
| Apr 04, 2024 | Wedbush | Buy | Buy | Hold |
| Mar 26, 2024 | Needham | Buy | Buy | Hold |
| Mar 26, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Mar 26, 2024 | Cowen & Co. | Buy | Upgrade | |
| May 01, 2023 | Bank of America Securities | Neutral | Upgrade | |
| Mar 07, 2023 | Credit Suisse | Outperform | Outperform | Hold |
| Jan 11, 2023 | Credit Suisse | Outperform | Outperform | Hold |
| Nov 15, 2022 | Credit Suisse | Outperform | Outperform | Hold |
| Nov 14, 2022 | Needham | Buy | Buy | Hold |
Stoke Therapeutics's last stock rating was published by Cowen & Co. on Sep 11, 2024. The company gave STOK a "Buy" rating, the same as its previous rate.
Stoke Therapeutics Financial Forecast
Stoke Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $3.31M | $-2.48M | $5.15M | $3.27M | $2.90M | $3.23M | $3.00M |
| Avg Forecast | $10.07M | $2.58M | $2.83M | $2.83M | $4.20M | $3.83M | $3.70M | $3.26M | $3.66M | $3.64M | $3.44M | $3.00M | $2.86M | $2.72M | $2.64M | $50.00M |
| High Forecast | $14.10M | $3.60M | $3.95M | $4.11M | $4.33M | $3.86M | $3.70M | $3.26M | $4.95M | $3.64M | $4.82M | $4.20M | $3.14M | $2.72M | $2.64M | $50.00M |
| Low Forecast | $5.42M | $1.39M | $1.52M | $1.54M | $3.79M | $3.80M | $3.70M | $3.26M | $2.48M | $3.64M | $1.85M | $1.61M | $2.62M | $2.72M | $2.64M | $50.00M |
| # Analysts | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.91% | -0.72% | 1.72% | 1.14% | 1.07% | 1.22% | 0.06% |
Stoke Therapeutics's average Quarter revenue forecast for Dec 23 based on 6 analysts is $3.66M, with a low forecast of $2.48M, and a high forecast of $4.95M. STOK's average Quarter revenue forecast represents a 10.75% increase compared to the company's last Quarter revenue of $3.31M (Sep 23).
Stoke Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-27.23M | $-33.26M | $-24.69M | $-27.18M | $-26.76M | $-25.24M | $-24.55M |
| Avg Forecast | $2.01M | $515.00K | $565.00K | $565.00K | $840.00K | $765.71K | $740.54K | $652.05K | $732.70K | $728.57K | $688.89K | $600.00K | $572.53K | $544.44K | $528.12K | $-60.23M |
| High Forecast | $2.82M | $720.54K | $790.49K | $821.82K | $865.98K | $772.07K | $740.57K | $652.07K | $990.13K | $728.59K | $963.83K | $839.46K | $628.39K | $544.44K | $528.12K | $-48.18M |
| Low Forecast | $1.08M | $277.13K | $304.04K | $308.18K | $757.73K | $759.36K | $740.51K | $652.02K | $495.07K | $728.56K | $370.70K | $322.87K | $523.66K | $544.44K | $528.12K | $-72.27M |
| Surprise % | - | - | - | - | - | - | - | - | - | -37.38% | -48.28% | -41.15% | -47.46% | -49.15% | -47.79% | 0.41% |
undefined analysts predict STOK's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Stoke Therapeutics's previous annual EBITDA (undefined) of $NaN.
Stoke Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | $-24.54M | $-30.65M | $-18.30M | $-22.05M | $-24.08M | $-23.22M | $-24.40M |
| Avg Forecast | $-32.49M | $-36.15M | $-33.71M | $-33.05M | $-20.95M | $-29.30M | $-30.88M | $-34.36M | $-34.29M | $-35.64M | $-35.76M | $-39.49M | $-40.17M | $-38.16M | $-38.34M | $-61.10M |
| High Forecast | $-12.98M | $-14.44M | $-13.47M | $-31.83M | $-12.13M | $-11.71M | $-12.34M | $-13.73M | $-26.55M | $-14.24M | $-14.29M | $-15.78M | $-35.71M | $-38.16M | $-38.34M | $-48.88M |
| Low Forecast | $-49.35M | $-54.91M | $-51.20M | $-34.28M | $-29.77M | $-44.50M | $-46.90M | $-52.19M | $-39.26M | $-54.12M | $-54.32M | $-59.98M | $-45.27M | $-38.16M | $-38.34M | $-73.32M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.69% | 0.86% | 0.46% | 0.55% | 0.63% | 0.61% | 0.40% |
Stoke Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. STOK's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Stoke Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | $10.27M | $10.23M | $10.21M | $9.38M | $9.94M | $10.11M | $9.49M |
| Avg Forecast | $21.85M | $5.58M | $6.13M | $6.13M | $9.11M | $8.30M | $8.03M | $7.07M | $7.95M | $7.90M | $7.47M | $6.51M | $6.21M | $5.76M | $5.59M | $23.51M |
| High Forecast | $30.57M | $7.81M | $8.57M | $8.91M | $9.39M | $8.37M | $8.03M | $7.07M | $10.74M | $7.90M | $10.45M | $9.10M | $6.81M | $5.76M | $5.59M | $28.22M |
| Low Forecast | $11.76M | $3.01M | $3.30M | $3.34M | $8.22M | $8.23M | $8.03M | $7.07M | $5.37M | $7.90M | $4.02M | $3.50M | $5.68M | $5.76M | $5.59M | $18.81M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.30% | 1.37% | 1.57% | 1.51% | 1.73% | 1.81% | 0.40% |
Stoke Therapeutics's average Quarter SG&A projection for Dec 23 is $7.95M, based on 6 Wall Street analysts, with a range of $5.37M to $10.74M. The forecast indicates a -22.64% fall compared to STOK last annual SG&A of $10.27M (Sep 23).
Stoke Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.55 | $-0.00 | $-0.43 | $-0.56 | $-0.61 | $-0.59 | $-0.65 |
| Avg Forecast | $-0.58 | $-0.64 | $-0.60 | $-0.59 | $-0.37 | $-0.52 | $-0.55 | $-0.61 | $-0.61 | $-0.63 | $-0.63 | $-0.70 | $-0.71 | $-0.68 | $-0.69 | $0.36 |
| High Forecast | $-0.23 | $-0.26 | $-0.24 | $-0.56 | $-0.22 | $-0.21 | $-0.22 | $-0.24 | $-0.47 | $-0.25 | $-0.25 | $-0.28 | $-0.63 | $-0.68 | $-0.69 | $0.36 |
| Low Forecast | $-0.88 | $-0.97 | $-0.91 | $-0.61 | $-0.53 | $-0.79 | $-0.83 | $-0.93 | $-0.70 | $-0.96 | $-0.96 | $-1.06 | $-0.80 | $-0.68 | $-0.69 | $0.36 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.87% | 0.00% | 0.61% | 0.79% | 0.89% | 0.86% | -1.80% |
According to undefined Wall Street analysts, Stoke Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to STOK previous annual EPS of $NaN (undefined).
Stoke Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PASG | Passage Bio | $0.58 | $6.00 | 934.48% | Buy |
| BDTX | Black Diamond Therapeutics | $2.44 | $20.00 | 719.67% | Buy |
| ADAP | Adaptimmune Therapeutics | $0.58 | $4.00 | 589.66% | Buy |
| RLAY | Relay Therapeutics | $4.48 | $18.00 | 301.79% | Buy |
| ARVN | Arvinas | $17.55 | $58.50 | 233.33% | Buy |
| PLRX | Pliant Therapeutics | $10.74 | $35.50 | 230.54% | Buy |
| STOK | Stoke Therapeutics | $10.51 | $26.50 | 152.14% | Buy |